Abstracts tagged "Lupus"

Abstract Number: 461 • 2018 ACR/ARHP Annual Meeting
Ofatumumab Use in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Experience
Anna Carmela Sagcal-Gironella¹, Eyal Muscal², Andrea A. Ramirez¹, Monica Marcus³, Miriah Gillispie¹, William Blaine Lapin¹ and Marietta M. De Guzman⁴, ¹Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Department of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX, ³Deaprtment of Pediatrics, Division of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Ofatumumab is a fully human anti-CD20 monoclonal antibody that has been approved for the treatment of chronic lymphocytic leukemia. It has been increasingly used…
Abstract Number: 750 • 2018 ACR/ARHP Annual Meeting
Positive Remodeling Index and Low Attenuation Non-Calcified Coronary Plaques: Markers of Vulnerable Coronary Plaques in Systemic Lupus?
George Stojan¹, Laurence Magder² and Michelle Petri³, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Department of Epidemiology, University of Maryland, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Accelerated atherosclerosis leading to premature coronary artery disease remains the major cause of late death in SLE. Positive remodeling index and presence of low…
Abstract Number: 1709 • 2018 ACR/ARHP Annual Meeting
Utilization of Complementary and Integrative Medicine Among Lupus Patients:a Patient Centered Analysis of Perceived Effectiveness and Preference
Lindsey Warner and Shazia Beg, University of Central Florida College of Medicine, Orlando, FL
Background/Purpose: Lupus is an autoimmune disease with multitude of symptoms that are often not fully controlled by standard biomedical treatments. This study was designed to…
Abstract Number: 2118 • 2018 ACR/ARHP Annual Meeting
Prevalence of Acquired Activated Protein C Resistance and Anti-Protein C Antibodies in Systemic Lupus Erythematosus
Giuseppe Alvise Ramirez^1,2,3,4, Hannah Cohen^5,6, David A. Isenberg^4,7 and Maria Efthymiou⁵, ¹Università Vita-Salute San Raffaele, Milan, Italy, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ³Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milan, Italy, ⁴Department of Rheumatology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁵Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom, ⁶Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁷University College London, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterised by increased cardiovascular risk, with a 5-20 fold increased risk for venous thromboembolism (VTE)…
Abstract Number: 2833 • 2018 ACR/ARHP Annual Meeting
Complement Activation Is a Feature of Diseases in the Lupus Spectrum
Rosalind Ramsey-Goldman¹, Roberta Alexander², Elena Massarotti³, Daniel J. Wallace⁴, Sonali Narain⁵, Cristina Arriens⁶, Christopher E. Collins⁷, Amit Saxena⁸, Chaim Putterman⁹, Kenneth C. Kalunian¹⁰, Armida Sace², Rowena Lafon², Tyler O'Malley², JoAnne Ligayon², Claudia Ibarra², John Conklin², Thierry Dervieux² and Arthur Weinstein⁷, ¹FSM, Northwestern University, Chicago, IL, ²Exagen Diagnostics, Inc., Vista, CA, ³Brigham and Women's Hospital, Boston, MA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Northwell Health, Great Neck, NY, ⁶Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, ⁸NYU Langone Health, New York, NY, ⁹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ¹⁰Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: We showed previously that complement activation - cell-bound complement activation products (CB-CAPS) or multi-analyte assay panel (MAP) - is a sensitive and specific biomarker…
Abstract Number: 466 • 2018 ACR/ARHP Annual Meeting
Improving Pneumococcal Vaccination Rates in Childhood-Onset SLE Patients at a Large Tertiary Care Center: The Path to Creating a More Sustainable Model of Vaccination with the Help of EMR
Saimun Singla and Marietta M. De Guzman, Pediatric Immunology, Allergy and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Streptococcus pneumonia is a leading cause of illness in children worldwide and can lead to death in those with an immunosuppressed status. Given the…
Abstract Number: 751 • 2018 ACR/ARHP Annual Meeting
Coronary Plaque Burden in Patients with Lupus Compared to Healthy Volunteers
George Stojan¹, Matthew Budoff², Laurence Magder³, Jessica Li⁴, Armin Zadeh⁵, Erik Barr⁶ and Michelle Petri⁵, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Cardiology, Harbor-UCLA Medical Center, Torrance, CA, ³Department of Epidemiology, University of Maryland, Baltimore, MD, ⁴Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Accelerated atherosclerosis leading to premature coronary artery disease remains the major cause of late death in SLE. We sought to characterize noncalcified and calcified…
Abstract Number: 1714 • 2018 ACR/ARHP Annual Meeting
Global Consensus Building and Prioritization of Major Challenges in Lupus Diagnosis, Care, Treatment and Research
Karin Tse¹, R. Paola Daly¹, Leslie Hanrahan², Annick Anderson³, Kathleen Arntsen⁴, Sang-Cheol Bae⁵, Ian N. Bruce⁶, Karen Costenbader⁷, Thomas Dörner⁸, Amy H. Kao⁹, Susan Manzi¹⁰, Eric Morand¹¹, Sandra Raymond¹, Brad H. Rovin¹², Laura E. Schanberg¹³, Victoria P. Werth¹⁴, Joan Von Feldt¹⁵ and Kenneth Getz³, ¹Lupus Foundation of America, Washington, DC, ²Lupus Foundation of America, Washington DC, DC, ³Tufts Center for the Study of Drug Development, Boston, MA, ⁴Lupus and Allied Diseases, Inc., Verona, NY, ⁵Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, United Kingdom, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁸Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany, ⁹EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ¹⁰Autoimmunity Institute and Medicine Institute, Allegheny Health Network, Pittsburgh, PA, ¹¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ¹²Ohio State University Medical Center, Columbus, OH, ¹³Duke University Medical Center, Durham, NC, ¹⁴Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁵GlaxoSmithKline, Philadelphia, PA
Background/Purpose: The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus initiative seeking to identify and prioritize top barriers in lupus impacting…
Abstract Number: 2124 • 2018 ACR/ARHP Annual Meeting
Bacterial Biofilm Product Curli/Edna Induces NETs and Serum Anti-Curli/Edna Levels Correlate with Bacteriuria and Lupus Activity
Ryan Pachucki¹, Chelsea Corradetti², Stefania Gallucci³, Cagla Tukel³, Sarah Tursi³, Laura Nicastro³, Lynne Kohler², Yaj Ghadiali⁴, Laurie Kilpatrick⁵ and Roberto Caricchio¹, ¹Medicine Rheumatology, Lewis Katz School of Medicine, Philadelphia, PA, ²Rheumatology, Lewis Katz School of Medicine, Philadelphia, PA, ³Microbiology and Immunology, Lewis Katz School of Medicine, Philadelphia, PA, ⁴Medicine, Lewis Katz School of Medicine, Philadelphia, PA, ⁵Temple Lung Center, Lewis Katz School of Medicine, Philadelphia, PA
Background/Purpose: Infections are a major contributor to lupus disease. We have previously demonstrated that bacterial amyloid curli, produced by E.coli, can accelerate disease in mouse…
Abstract Number: 2846 • 2018 ACR/ARHP Annual Meeting
Foot and Lower Limb Characteristics in People with SLE: A Comparison with Age- and Sex-Matched Healthy Control Participants
Sarah Stewart¹, Ashok Aiyer², Nicola Dalbeth³ and Keith Rome⁴, ¹School of Podiatry, Auckland University of Technology, Auckland, New Zealand, ²School of Podiatry, The Auckland University of Technology, Auckland, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴School of Clinical Science, Health & Rehabilitation Research Institute, AUT University, Auckland, New Zealand
Background/Purpose: People with SLE report joint pain and swelling, impaired circulation, cutaneous lesions and foot deformity. Foot- and lower-limb-related functional impairment has also been described…
Abstract Number: 468 • 2018 ACR/ARHP Annual Meeting
Baseline Features and Outcomes of Pediatric-Onset Discoid Lupus Erythematosus: Interim Data Analysis of a Multicenter Retrospective Cohort Study
Lisa Arkin¹, Kevin A. Buhr², Cordellia Nguyen³, Heather Brandling-Bennett⁴, Leslie Castelo-Soccio⁵, Yvonne Chiu⁶, Benjamin F. Chong⁷, Lucia Diaz⁸, Marisa S. Klein-Gitelman⁹, Amy Paller¹⁰, Jennifer Schoch¹¹, Emily von Scheven¹², Victoria P. Werth¹³, Julie Grossman-Kranseler¹⁴, Andrew D. Hudson¹⁵, Erin M. Ibler¹⁶, Mariana C. Marques¹⁷, Reesa L. Monir¹¹, Elana Putterman¹⁸ and Kaveh Ardalan¹⁹, ¹Departments of Dermatology and Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Department of Biostatistics & Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Division of Dermatology; Department of Pediatrics, Seattle Children’s Hospital/University of Washington School of Medicine, Seattle, WA, ⁵Pediatrics, Section of Dermatology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁶Pediatrics and Dermatology, Medical College of Wisconsin, Milwaukee, WI, ⁷Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, ⁸Department of Pediatrics, Division of Dermatology, Dell Children’s Hospital, Austin, TX, ⁹Department of Pediatrics, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹⁰Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ¹¹Department of Dermatology, University of Florida School of Medicine, Gainesville, FL, ¹²Department of Pediatrics, Division of Rheumatology, University of California at San Francisco, San Francisco, CA, ¹³Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ¹⁴Departments of Pediatrics, Division of Dermatology, University of Washington School of Medicine, Seattle, WA, ¹⁵Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX, ¹⁶Departments of Dermatology and Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ¹⁷Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹⁸Children’s Hospital of Philadelphia, Department of Pediatrics, Section of Dermatology, Children’s Hospital of Philadelphia, Philadelphia, PA, ¹⁹Departments of Pediatrics and Medical Social Sciences, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Background/Purpose: Discoid lupus erythematosus (DLE) is rare in children. Prior studies suggest 25-30% of children with skin-limited DLE are diagnosed with systemic lupus erythematosus (SLE)…
Abstract Number: 763 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Characteristics and Outcome between Isolated and Classic Lupus Nephritis
Kubra Bugdayli¹, Cynthia S. Crowson², Ladan Zand³, Mariam P. Alexander⁴, Lynn D. Cornell⁴ and Vaidehi R. Chowdhary⁵, ¹Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Nephrology and Hypertension, Mayo Clinic, Rochester, MN, ⁴Anatomic Pathology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Comparison of clinical characteristics and outcome between isolated and classic lupus nephritisBackground/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE). Rarely,…
Abstract Number: 1843 • 2018 ACR/ARHP Annual Meeting
Improving Access to Rheumatology Care for High-Risk Lupus Patients Can Help Decrease Hospitalizations
Allen P. Anandarajah¹, Sean McMahon², Amanda Ostronic³, Changyong Feng⁴, Jennifer Anolik⁵ and Christopher T. Ritchlin⁶, ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²Quality office, University of Rochester Medical Center, Rochester, NY, ³University of Rochester Medical Center, Rochester, NY, ⁴Statistics, University of Rochester, Rochester, NY, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY
Background/Purpose: We previously demonstrated that a small group of high risk, high cost patients (HRHC) account for majority of the hospitalizations, length of stay (LOS)…
Abstract Number: 2126 • 2018 ACR/ARHP Annual Meeting
STAT4 Activation By Type I Interferons Regulates Pathogenic IL-21 and IFN-γ in Lupus
Xuemei Dong¹, Fotios Koumpouras², Joseph E. Craft³ and Jason Weinstein¹, ¹Rheumatology, Yale University School of Medicine, New Haven, CT, ²Internal Medicine, Rheumatology, Yale University School of Medicine, New Haven, CT, ³Department of Internal Medicine/Rheumatology, Yale University School of Medicine, New Haven, CT
Background/Purpose: Follicular helper T cells (Tfh) cells in lupus help shape the germinal center (GC) response by delivering contact-dependent and soluble signals, including the cytokines…
Abstract Number: 2851 • 2018 ACR/ARHP Annual Meeting
NF-Κappa b Signaling in the Myeloid Cell Lineage Drives the Pathogenesis of Immune-Mediated Nephritis
Samantha Chalmers¹, Sayra Garcia¹, Justine Shum¹, Leal Herlitz² and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Cleveland Clinic, Cleveland, OH, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Immune-mediated glomerulonephritis is a serious end organ pathology that commonly affects patients with systemic lupus erythematosus (SLE). Nephrotoxic serum nephritis, induced by passive transfer…

1
2
3
…
26
Next Page »